An observational study in Consciousness Disorder, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-05.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Consciousness Disorders with a site in France — 11 open to participants now, 11 under way, none of them phase 3. Consciousness Disorders · France.
Among the 27 studies in Consciousness Disorders with a site in France, this one is one of 5 that started in 2020, is one of 5 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 14th registered.
291 studies on the registry are indexed under Consciousness Disorders; 109 are open to participants now.
Browse Consciousness Disorders studies →11 of the 27 studies in Consciousness Disorders with a site in France are open now. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 15+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier St Anne · Sites in France
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 74 Consciousness Disorders studies recruiting now, 31 (42%) set no upper age limit and 24 (32%) stop at 75 or younger; 12 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 3
First in 2008; this study’s year is marked. 5 started in 2020.
This study's planned enrollment of 500 is above the median of 79 across 95 observational studies indexed under Consciousness Disorders.
Median enrollment 76 across the 22 interventional studies, 114 across the 5 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 27 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 6 studies filed under Consciousness Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Consciousness Disorders with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04534777Assistance Publique - Hôpitaux de ParisMultimodal Neuroprognostication in Disorders of Consciousness | 2027-05 |
| NCT07127224Centre Hospitalier St AnneConsciousness Prognosis Evaluation Using Olfactory Stimulations in Comatose Patients) | 2027-05-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Consciousness Disorders with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Disorders of consciousness frequently occur at the acute phase of brain injuries. For the most severe cases, consciousness impairment can be prolonged. To optimize the medical plan and the goal of care, it is fundamental to have precise tools to predict chances of recovery of consciousness and potential disability. Currently, multimodal assessment including behavioral, neurophysiological and neuroimaging technics is recommended. However, the respective predictive values of these markers are poorly understood and decision making is challenging when results are contradictory
Improved treatment of critically ill patients has resulted in increased patients' survival rates in Intensive Care Units (ICU). This is particularly true for brain injury such as traumatic brain injuries, cerebral hemorrhages or cardiac arrest. While some of these patients regain consciousness after a transient state known as coma, other will develop a prolonged disorder of consciousness (DoC) such as chronic unresponsive wakefulness syndrome (also known as vegetative state) or minimally conscious state, or will remain severely disabled. Consciousness diagnosis and prediction of recovery in DoC currently relies on standardized behavioral assessment and disease-specific markers. However, this strategy may fail to detect covert consciousness due to major sensory and motor deficits. Moreover, the DoC etiology and pathophysiology are heterogenous and most likely result from the combination of factors whose interplay still needs to be clarified. Consciousness detection in DoC is of great importance in term of medical management (e.g., pain management, communication), prognosis (e.g., orientation to adapted rehabilitation center to maximize chance of recovery) and end-of-life discussions (e.g., withholding and/or withdrawing of life support discussion). Furthermore, taking care of these patients can be very stressful due to the high levels of uncertainty associated to their potential of recovery. For all these reasons it is critical to develop personalized diagnosis and prognosis assessment tools that can allow better decisions.
The M-NeuroDoC study will take advantage from the state-of-the-art multimodal assessment ongoing at our institution for both acute and chronic patients in order to improve recovery prediction.
Indeed, our multimodal assessment practice constitutes a great and unique opportunity to better understand the respective diagnostic and prognostic accuracy performances of markers such as behavioral, electrophysiological and neuroimaging that are routinely performed at our institution.
The overall outcome of this project will allow to draw better single-patient predictions of state, prognosis, and rehabilitation strategies and furthermore, a better understanding the pathophysiological mechanisms behind DoC that could result in groundbreaking new personalized therapeutic approaches.
Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years.
Data of interest will be:
Patients with consciousness disorder (acute sub-acute or chronic for which our expertise is requested to better characterize the diagnostic and prognosis of recovery) or with Brain injuries on CT or MRI
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The overall outcome of this project will allow to draw better single-patient predictions of state, prognosis, and rehabilitation strategies and furthermore, a better understanding the pathophysiological mechanisms behind DoC that could result in groundbreaking new personalized therapeutic approaches. Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years.
Other: repeated neurological, behavioral assessments and conventional, quantitative and functional brain imagery
Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years.
prognosis accuracy of respective predictive markers of consciousness recovery
Calculation of the value (Chi2 tests, specificity, sensitivity, positive and negative predictive values of each tests and of their combinations to distinguish patients states and outcome (24-month GOS-E ≥ 4 or \< 4).
Time frame: 24 MONTHS
GOS-E Glasgow outcome scale - Extended
Evolution of GOS-E (Glasgow outcome scale - Extended) scale from category 1 ==\> Death to category 8: good recovery upper ==\>no current problems related to the brain injury that affect daily life
Time frame: 6, 12 and 18 months
Started Sep 2020 (actual). Primary completion is estimated for May 2027, 80 months after the start.
Of 57 non-industry observational studies under Consciousness Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 95. This study's planned 80 months is above that.
Counting every sponsor, half of 59 studies reached it within 40 months; a quarter within 22 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →